Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, released Q1 2026 earnings on April 30, 2026, posting an EPS of $1.99 that surpassed the consensus estimate of $0.87 by $1.12, MarketBeat as of 05/12/2026. Separately, the company presented new data analyses from the HELIOS-B Phase 3 study of vutrisiran at Heart Failure 2026, demonstrating robust clinical benefits across ATTR-CM patient populations, Stock Titan as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Alnylam Pharmaceuticals: core business model

Alnylam Pharmaceuticals develops and commercializes RNAi therapeutics, a novel class of drugs that silence disease-causing genes. The company's pipeline targets rare genetic diseases, cardiometabolic conditions, and other unmet needs. Key approved products include ONPATTRO for hereditary ATTR amyloidosis with polyneuropathy, AMVUTTRA for ATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. These generate revenue primarily from US and global markets, with significant exposure to US healthcare spending.

Listed on Nasdaq under ALNY, Alnylam serves US investors through its focus on innovative biotech solutions amid rising demand for gene-silencing therapies in the US market.

Main revenue and product drivers for Alnylam Pharmaceuticals

Alnylam's revenue is driven by sales of its commercial RNAi drugs. In Q2 2025, quarterly revenue rose 17.3% year-over-year to $773.69 million, exceeding the $633.54 million consensus, per the July 31, 2025 earnings report, MarketBeat as of 07/31/2025. AMVUTTRA and ONPATTRO remain top contributors in ATTR amyloidosis treatment.

The Q1 2026 earnings beat underscores ongoing momentum, with EPS growth reflecting improved profitability as the company scales its portfolio.

Industry trends and competitive position

The RNAi therapeutics sector is expanding, with Alnylam leading in approved products. Competitors include Ionis Pharmaceuticals and Arrowhead Pharmaceuticals, but Alnylam's first-mover advantage in ATTR and porphyria positions it strongly. US market dominance in biotech innovation supports Alnylam's growth, as gene therapy demand rises.

Why Alnylam Pharmaceuticals matters for US investors

Alnylam Pharmaceuticals offers US investors exposure to cutting-edge RNAi technology via its Nasdaq listing. With products addressing rare diseases prevalent in the US, the company benefits from domestic reimbursement and clinical trial networks, making it relevant for portfolios focused on biotech innovation.

Conclusion

Alnylam Pharmaceuticals continues to advance with strong Q1 2026 earnings and positive vutrisiran data from HELIOS-B, reinforcing its leadership in RNAi therapeutics. These developments highlight operational progress and pipeline potential. Investors track upcoming catalysts like Q3 earnings on October 30, 2025.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.